DocumentsDate added
Original article:-
*1Raut Mohan ,1Rajurkar Sampda,1Malkar Vilas,1Joge Umesh,2Sapkal Pravin & 1Wagh Sanjay
Affiliation:-
1Assistant Professor Department of PSM,2Assistant Professor, Department of Anesthesia, Government Medical College, Akola,Maharastra,India.
Abstract:
Background: HIV/ AIDS is one of the most urgent threat to global public health. The changing trend in the country indicates that HIV infection is spreading in two ways: From urban to rural areas and from individuals practicing high risk behavior to the general population called Type 4 pattern. Auto drivers considered to be the one of the important mediator between this two population groups and hence studied here. Methods: The present study was carried out among the 346 auto drivers in urban area of Akola during July 2012 to Dec2012. Universal followed by convenience sampling method was used for selection of study participants. The preformed semi-structured questionnaire was used to collect the information. Result and conclusion: A total 346 auto rickshaw drivers were studied. Majority 331 (95.7%) of them have heard about HIV and around 50% knew that it is STI. Of the four routs of transmission, around 50% had correct knowledge about three route of transmission but the fourth one i.e infected mother to her foetus correct knowledge was seen in only 36%. 54% auto drivers ask for new needles before injection, 5% had sex with FSW and 5% had multiple sex partners. In the present sample of Auto drivers, though majority had heard of HIV / AIDS, they didn’t have correct knowledge about transmission of HIV / AIDS and safe sex practices. Hence health education on HIV / AIDS along with safe sex and condom promotion needs to be inculcated among them.
Key Words:- HIV/AIDS, Route of transmission, Safe sex practice.
References:-
1.Agarwal S. Acquired Immuno-Deficiency Syndrome. In Bhalwar R (ed). Text book of Public Health and Community Medicine, 1st edition. New Delhi, Department of Community Medicine AFMC, Pune In collaboration with WHO, India office, 2009; 1163-73.
2.Sarkar P, Mostofa G, Rahman M. Knowledge of fearfulness of HIV / AIDS between floating and frequently moving population of three metropolitans cities in Bangladesh. Jour of infectious disease and Immunity 2013; 5: 1-9.
3.Chaudhary S S, Nagargoje M M, Kubde S S, Bhardwaj A K, Singh R. Knowledge and attitude of auto-rickshaw drivers about HIV/AIDS and other sexually transmitted diseases. Indian J Dermatol Venereol Leprol 2011;77:197-9.
4.Singh G I, Girdha S, P.S. Gall, R.K. Soni, M. Satija, S. Sharma: HIV/AIDS Awareness Of Auto Rickshaw Drivers In Ludhiana City. Punjab – India. The Internet Journal of Health. 2008;8:266-71.
5.Jayadevan S, Jayakumary M. HIV/AIDS awareness among lorry/truck /taxi/auto drivers. Int Conf AIDS 2004;1511-6.
6.Chaturvedi S, Singh Z, Banerjee A, Khera A, Joshi R K, Dhrubajyoti D. Sexual behavior among long distance truck drivers. Indian J Community Medicine 2006;31: 153.
Article citation:-
Raut et al. Knowledge Attitude and Practice regarding HIV/ AIDS among auto drivers in one of the urban area of India. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 June; 31(31): 1229-1232.
Copyright © 2013 Raut et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Clinical updates:-
*1Obaid Mohammad, 2Pandey Rajesh, 3Singh Jasbir, 4Agrawal Bimal K & 3Sodhi Kuldip S.
Affiliation:-
1MD student, 2Associate Professor, 3Professor, Department of Biochemistry ,4Professor, Department of General Medicine, Maharishi Markandeshwar Institute of Medical Sciences and Research, Mullana, Ambala. Haryana, India.133207.
Abstract:
From being considered a mere end product of insulin synthesis, to its current role as an active biological molecule, C-peptide has evolved immensely. Its role in diabetic micro vascular complications like nephropathy, neuropathy and retinopathy has been substantially elucidated. Numerous signal transduction mechanisms have been implicated including those involving the stimulation of Na+K+-ATPase, endothelial nitric oxide synthetase, protein kinase C, mitogen activated protein kinases and phosphatidylinositol-3 kinases. Therapeutic trials of C-peptide in patients with diabetic nephropathy and neuropathy have shown considerable success, prompting some authors to propose the idea of labeling diabetes as a dual hormone disease, a somewhat premature, yet thought provoking proposal. The focus should now shift towards evaluating its role in type 2 diabetes mellitus and metabolic syndrome. Because of their complex pathogeneses, this role is less clear. However, it can safely be said that elucidating this association is only a matter of time. Altered C-peptide levels in non diabetic pathologies like cancers of colon, breast and prostate and in thyroid disorders are another interesting finding. Much more however needs to be done to explain the possible mechanisms of these alterations and suggest plausible clinical applications. The search for a C-peptide receptor still remains elusive. Its discovery, perhaps, can serve as the final nail in the coffin in deciphering the C-peptide puzzle.
Key Words:- Cancer, C-peptide, Complications, Diabetes mellitus, Insulin.
References:-
1.Steiner DF, Cunningham D, Spigelman L, Aten B. Insulin biosynthesis: Evidence for a precursor. Science. 1967 Aug 11;157(3789):697-700.
2.Wahren J, Kallas A, Sima AAF. The clinical potential of C-peptide replacement in type 1 diabetes. Diabetes. 2012 Apr;61(4):761-72.
3.Johansson BL, Sjoberg S, Wahren J. The influence of human C-peptide on renal function and glucose utilization in type 1 (insulin-dependent) diabetic patients. Diabetologia. 1992; 35:121–8.
4.Johansson BL, Kernell A, Sjoberg S, Wahren J. Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1. J Clin Endocrinol Metab. 1993;77:976–81.
5.Powers AC. Diabetes Mellitus. In:Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editors. Harrison's principles of internal medicine 18th edition. New York, Mc Graw Hill Companies 2012; p2968-75.
6.Sacks DB. Diabetes Mellitus. In:Burtis CA, Ashwood ER, Bruns DE. editors. Tietz textbook of clinical chemistry and molecular diagnostics 5th edition. New Delhi, Elsevier 2012; p1415-31.
7.Steiner DF. The proinsulin C-peptide-A multirole model. . Exp Diabesity Res. 2004 Jan-Mar;5(1):7–14.
8.Hills CE, Brunskill NJ. Intracellular signalling by C-Peptide. Exp Diabetes Res. [635158] 2008 [Cited 2013 may 24] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2276616/
9.Shafqat J, Melles E, Sigmundsson K, Johansson BL, Ekberg K, Alvelius G, et al. Proinsulin C-peptide elicits disaggregation of insulin resulting in enhanced physiological insulin effects. Cell Mol Life Sci. 2006 August;63(15):1805-11.
10.Hills CE, Brunskill NJ, Squires PE. C-peptide as a therapeutic tool in diabetic nephropathy. Am J Nephrol. 2010;31(5):389–97.
11.Hills CE, Al-Rasheed N, Al-Rasheed N, Willars GB, Brunskill NJ. C-peptide reverses TGF-β1-induced changes in renal proximal tubular cells: implications for treatment of diabetic nephropathy. Am J Physiol Renal Physiol. 2009 Mar;296(3):F614-21.
12.Stridh S, Sallstrom J, Friden M, Hansell P, Nordquist L, Palm F. C-peptide normalizes glomerular filtration rate in hyperfiltrating conscious diabetic rats. Adv Exp Med Biol. 2009;645:219-25.
13.Stevens MJ, Zhang W, Li F. C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor rats. Am J Physiol Endocrinol Metab. [E497-505]. 2004 Sep
[cited 2013 April 24]; 287(3): Available from http://www.ncbi.nlm.nih.gov/pubmed/15126237
14.Zhang W, Kamiya H, Ekberg K, Wahren J, Sima AA. C-peptide improves neuropathy in type 1 diabetic BB/Wor-rats. Diabetes Metab Res Rev. 2007 Jan; 23(1):63-70.
15.Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabet Med. 2000 Mar; 17(3):181-9.
16.Ekberg K, Brismar T, Johansson BL, Lindstrom P, Juntti-Berggren L, Norrby A, et al.. C-peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care. 2007 Jan;30(1):71-6.
17.Sima AA, Zhang W, Kreipke CW, Rafols JA, Hoffman WH. Inflammation in diabetic encephalopathy is prevented by C-peptide. Rev Diabet Stud. 2009 Spring;6(1):37-42.
18.Chakrabarti S, Khan ZA, Cukiernik M, Zhang W, Sima AA. C-peptide and retinal microangiopathy in diabetes. Exp Diabesity Res. 2004 Jan-Mar; 5(1):91-6
19.Yoon HJ, Cho YZ, Kim JY, Kim BJ, Park KY, Koh GP, et al. Correlations between glucagon stimulated C-peptide levels and microvascular complications in type 2 diabetes patients. Diabetes Metab J. 2012;36(5):379-87.
20.Bo S, Gentile L, Castiglione A, Prandi V, Canil S, Ghigo E, et al. C-peptide and the risk for incident complications and mortality in type 2 diabetic patients: a retrospective cohort study after a 14-year follow-up. Eur J Endocrinol. 2012 Aug;167(2):173-80.
21.Tajiri Y, Kimura M, Mimura K, Umeda F. Variation of fasting serum C-peptide level after admission in Japanese patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2009 Sep;11(9):593-9.
22.Oran PE, Jarvis JW, Borges CR, Nelson RW. C-peptide microheterogeneity in type 2 diabetes populations. Proteomics Clin Appl. 2010 Jan;4(1):106-11.
23.Kim ST, Kim BJ, Lim DM, Song IG, Jung JH, Lee KW, et al. Basal C-peptide level as a surrogate marker of subclinical atherosclerosis in type 2 diabetic patients. Diabetes Metab J. 2011 Feb; 35(1):41-9.
24.Manzella D, Ragno E, Abbatecola AM, Grella R, Paolisso AG. Residual c-peptide secretion and endothelial function in patients with type ii diabetes. Clin Sci (Lond). 2003 Jul; 105(1):113-8.
25.Najeeb Q, Masood I, Ishaq S, Pandey R, Bhaskar N, Kaur H, et al. Glycated hemoglobin: Better diagnostic parameter than fasting plasma glucose levels: A comparative study in patients undergoing dental surgery. JIMSA. 2012; 25:79-80.
26.Badyal A, Sodhi KS, Pandey R, Singh J. Emerging clinical significance of magnesium in Type 2 Diabetes Mellitus. Curr Trends Biotechnol Chem Res. 2012; 1:53-9.
27.Hansen A, Johansson BL, Wahren J, von Bibra H. C-peptide exerts beneficial effects on myocardial blood flow and function in patients with type 1 diabetes. Diabetes, 2002;51: 3077-82.
28.Hills CE, Brunskill NJ. Cellular and physiological effects of C-peptide. Clin Sci (Lond). 2009 Apr;116(7):565-74.
29.Katz LE, Jawad AF, Ganesh J, Abraham M, Murphy K, Lipman TH. Fasting c-peptide and insulin-like growth factor-binding protein-1 levels help to distinguish childhood type 1 and type 2 diabetes at diagnosis. Pediatr Diabetes. 2007 Apr;8(2):53-9.
30.M. Thunander, C. Torn, C. B. Petersson, Ossiansson, J. Fornander Landin-Olsson M. Levels of C-peptide, body mass index and age, and their usefulness in classification of diabetes in relation to autoimmunity, in adults with newly diagnosed diabetes in Kronoberg, Sweden, Eur. J. Endocrinol. 2012; 166 : 1021-9.
31.Besser RE, Shields BM, Hammersley SE, Colclough K, McDonald TJ, Gray Z, et al. Home urine C-peptide creatinine ratio testing can identify type 2 and MODY in pediatric diabetes. Pediatr Diabetes [epub ahead of print]. 2013 Jan 4 [ cited 2013 May 24]; Available at : http://www.ncbi.nlm.nih.gov/pubmed/23289766.
32.Delvaux T, Buekens P, Thoumsin H, Dramaix M, Collette J. Cord C-peptide and insulin-like growth factor-I, birth weight, and placenta weight among North African and Belgian neonates. Am J Obstet Gynecol. 2003 Dec; 189(6):1779-84.
33.Akin M, Ceran O, Atay E, Atay Z, Akin F, Akturk Z. Postpartum maternal levels of hemoglobin A1c and cord C-peptide in macrosomic infants of non-diabetic mothers. J Matern Fetal Neonatal Med. 2002; 12:274-6.
34.Dube MC, Morisset AS, Tchernof A, Weisnagel SJ. Cord blood C-peptide levels relate to the metabolic profile of women with and without gestational diabetes. Acta Obstet Gynecol Scand. 2012 Dec; 91(12):1469-73
35.Regnault N, Botton J, Heude B, Forhan A, Hankard R, Foliguet B. Higher cord C-peptide concentrations are associated with slower growth rate in the 1st year of life in girls but not in boys. Diabetes. 2011 Aug; 60(8):2152-9.
36.Denner L, Bodenburg Y, Zhao JG, Howe M, Cappo J, Tilton RG. Directed engineering of umbilical cord blood stem cells to produce C-peptide and insulin. Cell Prolif. 2007 Jun; 40(3):367-80.
37.Mavrakanas T, Frachebois C, Soualah A ,Aloui F, Julier I , Bastide D. C-peptide and chronic complications in patients with type-2 diabetes and the metabolic syndrome. Presse Med. 2009;38:1399-1403.
38.Gajewska J , Klemarczyk W , Ambroszkiewicz J , Chełchowska M , Riahi A , Zielińska A, et al. Effect of weight reduction programme on C-peptide concentration and lipid profile in obese children aged 4 to 10 years. Med Wieku Rozwoj. 2010;14:357-64.
39.Lee WJ, Chong K, Ser KH, Chen JC, Lee YC, Chen SC, et al. C-peptide predicts the remission of type 2 diabetes after bariatric surgery. Obes Surg. 2012 Feb;22(2):293-8.
40.Jena M, Riboli E, Cleveland RJ, Norat T, Rinaldi S, Nieters A, et al. Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2007 Jul 15;121(2):368-76.
41.Vidal AC, Lund PK, Hoyo C, Galanko J, Burcal L, Holston R, et al. Elevated C-peptide and insulin predict increased risk of colorectal adenomas in normal mucosa. BMC Cancer 2012; 12:389.
42.Wu K, Feskanich D, Fuchs CS, Chan AT, Willett WC, Hollis BW, Pollak MN, et al. Interactions between plasma levels of 25-hydroxyvitamin D, insulin-like growth factor (IGF)-1 and C-peptide with risk of colorectal cancer. PLoS One [e28520]. 2011 [cited 2013 may 24]; 6(12).
43.Schairer C, Hill D, Sturgeon SR, Fears T, Pollak M, Mies C, et al. Serum concentrations of IGF-I, IGFBP-3 and C-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women. Int J Cancer. 2004 Feb 20; 108(5):773-9.
44.Irwin ML, Duggan C, Wang CY, Smith AW, McTiernan A, Baumgartner RN, et al. Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J Clin Oncol. 2011 Jan 1; 29(1):47-53.
45.Eliassen AH, Tworoger SS, Mantzoros CS, Pollak MN, Hankinson SE. Circulating insulin and C-peptide levels and risk of breast cancer among predominately premenopausal women. Cancer Epidemiol Biomarkers Prev. 2007 Jan; 16(1):161-4.
46.Griffith ML, Jagasia MH, Misfeldt AA, Chen H, Engelhardt BG, Kassim A, et al. Pretransplantation C-Peptide level predicts early posttransplantation diabetes mellitus and has an impact on survival after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2011; 17:86-92.
47.Miller EH, Harrison JS, Radoshitzky SR, Higgins CD, Chi X, Dong L, et al. Inhibition of ebola virus entry by a C-peptide targeted to endosomes. J Biol Chem. 2011 May 6;286(18):15854-61.
48.Neuhouser ML, Till C, Kristal A, Goodman P, Hoque A, Platz EA, et al. Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Prev Res. (Phila). 2010; 3:279-89.
49.Purohit P. Estimation of serum insulin, Homeostasis model assessment-insulin resistance and C-peptide can help identify possible cardiovascular disease risk in thyroid disorder patients. Indian J Endocrinol Metab. 2012;16 (Suppl.1):S97–S103.
50.Patel N, Taveira TH, Choudhary G, Whitlatch H, Wu WC. Fasting serum C-Peptide levels predict cardiovascular and overall death in nondiabetic adults. J Am Heart Assoc. [e003152]. 2012 Dec [Cited 2013 May 24]; 1(6): Available from: http://www.ncbi.nlm.nih.gov/pubmed/23316320.
Article citation:-
Obaid Mohammad et al. The rediscovery of C-Peptide: A clinical update. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 June; 31(31): 1221-1228.
Copyright © 2013 Obaid Mohammad et al.. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article:-
*1Ajay Kumar A, 2M. R.Vasanthan & 3N. Kannan
Affiliations:-
1Associate Professor, 2 Professor, 3Assistant Professor, Department of Anaesthesiology and Critical Care, Sree Balaji Medical College and Hospital (7, works road, Chromepet, Chennai – 600044), India.
Abstract:-
A surgical procedure performed on a patient admitted and discharged on the same day of surgery is an accepted and well-established practice in modern medicine today. The principal arguments in favour of this practice are minimizing cost and making hospital resources available for more number of patients, as each patient spends a shorter period in the hospital. The availability of shorter acting anaesthetic agents with better recovery profile has made general anaesthesia applicable in day case procedures. The ‘clear headedness’ of recovery enables the patients to be discharged from the hospital just a few hours after surgery. The drugs found most suitable for this technique are Propofol and Sevoflurane. The present study compares the recovery characteristics of these two drugs and their usefulness in ambulatory anaesthesia. We compared the recovery profile of 40 patients coming for surgeries lasting less than an hour. Aldrete scoring was used to assess early recovery and PADSS scoring used for assessing ‘Home Readiness’. ‘Home Readiness’ was sooner while using Sevoflurane VIMA(Volatile Induction and Maintenance Anesthesia) as compared to Propofol TIVA(Total Intravenous Anesthesia) making Sevoflurane the ideal choice for Day case surgery.
Keywords: Propofol TIVA, Sevoflurane VIMA, Recovery scores, Day case anaesthesia.
References:
1.Ronald D. Miller. Outpatient Anesthesia 2000; 5(2): 2213 – 40.
2.Cedric Prys-Roberts and Burnell R. Brown Jr 1996; 1(2) : Chapters 121 and 123.
3.Robert K. Stoelting 1999; Pharmacokinetics and Pharmacodynamics of Injected and Inhaled drugs. 4-36, Inhaled anesthetics comparative pharmacology. 38-65, Nonbarbiturate induction drugs – Propofol. 140-145
4.American Society of Anaesthesiologists – Committee of Ambulatory surgical care, communication; 2003.
5.Jerry A. Dorsch and Susan E. Dorsch 1998; Airway Equipment – Laryngeal mask airways 463-504
6.A.MOFFAT, MB, CHB, FRCA, P. M. CULLEN, MB, CHB, DRCOG, FRCA. Comparison of two standard techniques of general anaesthesia for day-case cataract surgery. Br. J. Anaesth. 1995; 74:145-8.
7.Dexter F, Tinker JH.Comparisons between desflurane and isoflurane or propofol on time to following commands and time to discharge. A metaanalysis. Anesthesiology. 1995 Jul; 83(1):77-82.
8.Boldt, Joachim, MD; Jaun, Norbert, MD; Kumle, Bernhard, MD; Heck, Martin, MD; Mund, Klaus, MD. Economic Considerations of the Use of New Anesthetics: A Comparison of Propofol, Sevoflurane, Desflurane, and Isoflurane. Anesth Analg 1998; 86:504–9.
9.Keller, C., MD; Sparr, H. J., MD; Luger, T. J., MD; Brimacombe, J, MB CHB FRCA MD. Patient outcomes with positive pressure versus spontaneous ventilation in non-paralysed adults with the laryngeal mask. Can J Anaesth 1998 / 45 / 564-567
10.Sear, J. W.; Glen, J. B. Propofol administered by a manual infusion regimen. Br. J. Anaesth. 1995; 74:362-7.
11.Figueredo E, Vivar-Diago M, Muñoz-Blanco F.Laryngo-pharyngeal complaints after use of the laryngeal mask airway. Can J Anaesth 1999 ; 46 :220-5.
12.Joshi GP, Inagaki Y, White PF, Taylor-Kennedy L, Wat LI, Gevirtz C, McCraney JM, McCulloch DA. Use of the Laryngeal Mask Airway as an alternative to the Tracheal tube during ambulatory anesthesia. Anesth Analg. 1997 Sep; 85(3):573-7.
13.McCrory, Connail R., MB FFARCSI; McShane, Alan J.,BSC FRCPI FFARCSI; Gastroesophageal reflux during spontaneous respiration with the laryngeal mask airway: Can J Anaesth 1999 ;46 :268-70.
14.Liao R, Li JY, Liu GY. Comparison of sevoflurane volatile induction/ maintenance anaesthesia and propofol- remifentanil total intravenous anaesthesia for rigid bronchoscopy under spontaneous breathing for tracheal/bronchial foreign body removal in children. Eur J Anaesthesiol. 2010 Nov; 27(11):930-4.
15.Watson KR, Shah MV. Clinical comparison of 'single agent' anaesthesia with sevoflurane versus target controlled infusion of propofol.Br J Anaesth. 2000 Oct;85(4):541-6.
Article citation:-
Ajay Kumar. A, M. R. Vasanthan & N. Kannan. Comparison of recovery from propofol TIVA and sevoflurane VIMA in day case surgeries. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 June; 31(31): 1214-1220.
Copyright © 2013 Ajay Kumar A, R.Uma & M. R.Vasanthan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Research article:-
Jai Ram Kaundal1*, Nishant Negi2,V.P. Sharma3,G.K Singh4
Affiliation:-
1Assistant Professor,2Lecturer,Department. of Orthodontics and Dentofacial Orthopedics;H.P.Govt. Dental College and Hospital; Shimla, Himachal Pradesh- 171001; India.
3Professor and Principal, Dental College Barabanki U.P.,India.
4Professor, Deptt. Of orthodontics and Dentofacial Orthopedics,K.G.M.U.,Lucknow,U.P.India.
Abstract:
Aim:- To evaluate crowding in relation to tooth size, arch size and arch form in North-East Indian population. Material and methods-This study was conducted on study casts obtained from 40 subjects of North East origin who were divided into crowded and noncrowded group. For each of the subjects cumulative tooth width, arch width, arch length, arch perimeter, overjet, overbite, curve of spee, palatal vault height and arch form were measured. Student’s t test was used to compare two groups.
Results:- Crowded male samples had increased total tooth material with decreased arch perimeter and intermolar width. Crowded female sample had increased total tooth material with reduced arch perimeter and arch length. Conclusion:- Crowding was associated with reduced arch perimeter, reduced intermolar width and increased total tooth material in North-East Indian population.
Key Words: Arch form, Arch size, Crowding.
References:
1.Nance HN. The limitations of orthodontic treatment. Am J Orthod Oral Surg 1947; 33:177-223.
2.Lundstrom A. The etiology of crowding of teeth and its bearing on orthodontic treatment. Eur Orthod Soc (report)1951;176-91.
3.Mills LF. Arch width arch length and tooth size in young adult males. Angle Orthod 1964; 36:124-9.
4. Fastlicht J. Crowding of mandibular incisors. Am J Orthod 1970;58:156-63.
5.Howe RP, McNamara JA, O’Connor KA. An examination of dental crowding and its relationship to tooth size and arch dimensions. Am J Orthod 1983;83:363-73.
6. Corrucini RS, Pacciani E. Orthodontistry and dental occlusion in Etruscans. Angle Orthod 1989;59:61-4.
7.Morrees CFA, Reed RB. Biometrics of crowding and spacing in the mandible. Am J Phys Anthropol 1954;12:77-88.
8.Mills LF, Hamilton PH. Epidemiological studies of malalignment, a method for computing dental arch circumference. Angle Orthod 1965;35:244-8.
9.Radnzic et al. Dental crowding and its relationship to mesiodistal crown diameters and arch dimensions. Am J Orthod 1988; 94:50-6.
10.Riqueleme A , Green LJ. Palatal width, height and length in human twins. Angle Orthod 1970;40:71-9.
11.Chuck George C. Ideal arch form. Angle Orthod 1934;4:312-27.
12.Brunelle JA, Bhat M, Lipton JA. Prevalence and distribution of selected occlusal characteristics in U.S. population. J Dent Res 1991;75:706-13.
13.Proffit WR, Fields HW, Moray LJ. Prevalence of malocclusion and orthodontic treatment needs in the United States: estimates from the NHANES-III survey. Int J Adult Orthod Orthogn Surg 1998;13:97-106.
14.Hunter WS, Priest WR. Errors and discrepencies in measurements of tooth size. J Dent Res 1960;39:405-14.
15.Doris JM. Bernard BW, Kuftinec MM. A biometric study of tooth size and dental crowding. Am J Orthod 1981;79:326-36.
16.Walter DC. Changes in the face and dimensions of dental arches resulting from orthodontic treatment. Angle Orthod 1953;3:23.
17.Raberin, Laumon, Martin, Brunner. Form of dental arches. Am J Orthod 1993,Jul:67-72.
18.Kook YA, Najima K, Moon HB, McLaughlin RP, Sinclair PM. Comparison of arch forms between Korean and North American white populations. Am J Orthod Dentofac Orthop 2004;126:680-6.
19.Ling JY, Wong RW. Dental arch widths of southern Chinese. Angle Orthod 2009;79:54-63.
20.Lara-Carrillo E, Gonzalez-Perez JC, Kubodera-Itot, Montiel-Bastida NM, Esquivel-Pereyra GI. Dental arch morphology of Mazahua and Mestizo teenagers from central mexico. Braz J Oral Sci 2009;8:92-6.
21.Khin MT, Than W, Abdullah N, Jayasinghe JAP, Chandima GL. The maxillary arch and its relationship to cephalometric landmarks of selected Malay ethnic group. Mal J Med Sci 2005;12:29-38.
22.Hussein KW, Rajion ZA, Hassan R, Noor SN. Variations in tooth size and arch dimensions in Malay schoolchildren. Aust Orthod J 2009;25:163-8.
23. Barrett MJ, Brown T, Macdonald MR. Size of dental arches in a tribe of central Australian aborigines. J Dent Res 1965;44:912-20.
24.Patel VJ, Bhatia AF, Mahadevia SM, Italia S, Vaghamsi M. Dental arch form analysis in Gujrati males and females having normal occlusion. JIOS 2012;46(4):295-9.
25.Othman SA et al. Comparison of arch form between ethnic Malays and Malaysian aborigines in peninsular Malaysia. Korean J Orthod 2012;42(1):47-54.
Article citation:-
Kaundal Jai Ram et al. Evaluation of crowding in relation to tooth size, arch size and arch form in North-east Indian population. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 June; 31(31): 1199-1204.
Copyright © 2013 Kaundal Jai Ram et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article:-
Modi Syamal1*,2 & Chachan Smriti3,4
Affiliation:-
1Tutor, Department of microbiology, Patna Medical College, Patna, Bihar, India.
2Consultant microbiologist, Modi Diagnostics, Road number 11/F, Rajendra nagar, Patna-800016, Bihar, India.
3DNB Trainee (Family medicine), Apollo Gleneagles Hospital, Kolkata, India.
4Visiting consultant, Modi nursing home, Road number 11/F, Rajendra nagar, Patna-800016, Bihar, India.
Abstract:
Context: Urinary tract infection (UTI) is an important cause of morbidity especially in women, both in outpatient as well as in hospitalized settings. Prompt detection and treatment strategies are required for UTI, and in spite of the availability of a wide spectrum of antibiotics, UTI remains a major challenge for the clinician to treat especially with the emergence of new bacterial strains producing extended spectrum beta lactamases (ESBLs). Information on ESBL producing organisms causing UTI in India is limited. Current knowledge on antimicrobial susceptibility pattern of uropathogens is mandatory for appropriate therapy.
Aim: The aim of this study was to find out the prevalence of UTI at a medical centre in Patna, perform phenotypic characterization of the urinary isolates and study their antimicrobial susceptibility patterns so as to identify the ESBL producers in the population of different uropathogens.
Materials and Methods: Two hundred urinary isolates from patients of clinically suspected UTI, presenting to a multi-speciality nursing home in Patna, were analyzed in this study. Urine cultures were performed on 5% sheep blood agar and Mac Conkey agar. The isolates were identified by conventional methods. Antimicrobial sensitivity test was performed on Mueller Hinton agar by the Kirby Bauer disk diffusion method. The isolates resistant to cephotaxime were subjected to double disk synergy test method to detect ESBL production and the NCCLS-ESBL phenotypic confirmatory test to confirm ESBL production. Results: Females were found to suffer from UTI 1.85 times more frequently than males. Majority of patients (58.5%) were between 20-50 years of age. The gram negative bacilli were isolated more frequently (85.0%) than the gram positive cocci (15.0%). Majority of the isolates were Escherichia coli (60.0%) followed by Klebsiella spp. (17.5%) and Staphylococcus aureus (12.0%). The E. coli and Klebsiella isolates showed low sensitivity to ampicillin, cotrimoxazole and cephalosporins. All gram negative isolates were sensitive to imipenem. All gram positive isolates were sensitive to amoxycillin+clavulanate and vancomycin. Staphylococcus aureus strains showed low sensitivity towards ampicillin (21.78%) and cotrimoxazole (34.83%) but relatively higher sensitivities to the other antibiotics. 24.70% of gram negative bacilli were found to be ESBL producers, mainly 18 isolates of E.coli (15.0%) and 14 of Klebsiella spp. (40.0%). None of the gram positive isolates was found to produce ESBL. Among the 42 ESBL producers, 97.61% strains were resistant to ampicillin, 95.23% to cotrimoxazole, 85.5% to amikacin, 73.83% to ciprofloxacin and 69.04% to levofloxacin. The ESBL producing isolates of E.coli showed co-resistance of 94.4% against ampicillin and 88.88% to cotrimoxazole and those of Klebsiella spp. showed 100.0% co-resistance against ampicillin and cotrimoxazole. However, all the isolates of Enterobacteriaceae producing ESBL were sensitive to imipenem. Conclusions: Antibiotic resistance especially due to increasing prevalence of ESBL producers is becoming a big problem in the management of UTI patients. High rates of ESBL production may be due to indiscriminate use of extended spectrum antibiotics. Organisms confirmed to be ESBL producers should be reported resistant to all extended spectrum beta lactam antibiotics regardless of susceptibility results. It is important for clinical microbiology laboratory to be aware of these isolates and implement a method for detection of ESBL producing isolates. Active surveillance cultures, contact precautions for patients and judicious use of antimicrobials are required to significantly reduce the incidence of ESBL producers.
Key Words: Antimicrobial sensitivity, extended spectrum β lactamase, phenotypic, urine culture, urinary tract infection.
References:
1.Akram M, Shahid M, Khan AU. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in J N M C Hospital Aligarh, India. Annals of Clinical Microbiology and Antimicrobials 2007; 6: 4-10.
2.Rajan S, Prabavathy J. Antibiotic Sensitivity and Phenotypic Detection Of ESBL producing E.Coli Strains Causing Urinary Tract Infection In a Community Hospital, Chennai, Tamil Nadu, India. WebmedCentral Pharmaceutical Sciences 2012; 3(11): WMC003840.
3.Sobel JD, Kaye D. Urinary tract infections. In: Mandell GL, Bennett JE, Dolin R, editors. Principals and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingstone; 2000.
4.Tankhiwale SS, Jalgaonkar SV, Ahamad S, Hassani U. Evaluation of extended spectrum beta lactamase in urinary isolates. Indian J Med Res 2004; 120: 553-556.
5.Philippon A, Labia R, Jacoby G. Extended spectrum beta lactamases. Antimicrob Agents Chemother 1989; 33: 1131-6.
6.Katsanis GP, Spargo J, Ferraco MJ, Sutton L, Jacoby GA. Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended spectrum beta lactamases. J Clin Microbial 1994; 32: 691-6.
7.Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection to late generation cephalosporins. Annu Intern Med 1993; 119: 353-8.
8.Phillipon A, Fournier G, Paul G, Vedel G, Nevot P. Detection of distribution des beta lactamases a spectre elargi chezles enterobacteries. Med Mal Infect 1988; 12: 869-879.
9.Beckford-Ball J. Related Articles, Management of suspected bacterial urinary tract infection. Nurs Times 2006; 102(36): 25-6.
10.Girou E, Rioux C, Brun-Buisson C, Lobel B. Infection Committee of the French Association of Urology. The postoperative bacteriuria score: a new way to predict nosocomial infection after prostate surgery. Infect Control Hosp Epidemiol 2006; 27(8): 847-854.
11.Forbes BA, Sahm DF, Weissfeld AS, editors. Bailey and Scott’s Diagnostic Microbiology. 11th ed. St. Louis: Mosby, 2002.
12.Bauer AW, Kirby WMM, Sherris JC, Tuck M. Antibiotics susceptibility testing by a standardized single disc method. Am J Clin Pathol 1966; 45: 493-6.
13.National Committee for Clinical Laboratory Standards: Methods for Disk Susceptibility Tests for Bacteria That Grow Aerobically. NCCLS Document M2-A7. National Committee for Clinical Laboratory Standards 7th ed. Wayne, PA. 2000.
14.Miles RS, Amyes SGB. Laboratory control of antimicrobial therapy. In: Collee JG, Fraser AG, Marmion BP, Simmons A, editors. Mackie and McCartney Practical Medical Microbiology. 14th ed. Edinburgh: Churchill Livingstone; 2006.p.151-178.
15.National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing. International Supplement. NCCLS Committee for Clinical Laboratory Standards 11th ed. Wayne, PA. 2001.
16.Kumar MS, Lakshmi V, Rajagopalan R. Related Articles, Occurrence of extended spectrum beta-lactamases among Enterobacteriaceae spp. isolated at a tertiary care institute.Indian J Med Microbiol 2006; 24(3): 208-11.
17.Khan AU, Musharraf A. Plasmid mediated multiple antibiotic resistance in P. mirabilis isolated from the UTI patients. Medical Sci Mon 2004; 10: 598-602.
18.Grungberg RN, Leigh DA, Brumfitt W. The bacteriology of urinary tract infection: does it matter? Proc R Soc Med 1972 June; 65(6): 514–6.
19.Gales AC, Jones RN, Gordon KA, Sader HS et al. Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in South America, Sentry Antimicrobial Surveillance Programme (1998). Journ Antimicrob Chemother 2000; 45: 295-303.
20.Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med 2002; 113 (Suppl 1A): 145-95.
21.Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA1999; 281:736-8.
22.Jones RN, Rhomberg PR,Varnan DJ, Mathai D. A comparison of the antimicrobial activity of meropenem and selected broad spectrum antimicrobials tested against multidrug resistant gram negative bacilli including bacteraemic Salmonella spp. Initial studies for the MYSTIC programme in India. J Antimicrob Agents 2002; 20: 426-31.
23.Khurana S, Taneja N, Sharma M. Extended spectrum beta lacatamases mediated resistance in urinary tract isolates of family enterobacteriaceae. Indian J Med Res 2002; 116: 145-9.
24.Gupta V, Yadav A, Joshi RM. Antibiotic resistance pattern in uropathogen. Indian J Med Microbiol 2002; 20: 96-8.
25.Akata F, Tatman-Otcum M, Ozkan E, Tansel O, Otkum M, Tugrul M. Prevalence of extended spectrum beta lactamases producedby nosocomial isolates of enterobacteriacae in Trakata University Hospital, Turkey. New Microbial 2003; 26: 257-62.
26.Paterson DL. Recommendations for treatment of severe infections caused by Enterobacteriaceae producing Extended Spectrum Beta Lactamases (ESBLs) .Clin Microbiol Infect 2000; 6: 460-3.
27.Sanders CC, Thomson KS, Bradford PA. Problems with Detection of Beta Lactam Resistance among Nonfastidious Gram Negative Bacilli. Infect Dis Clin North Am 1993; 7: 411-24.
28.Schwaber MJ, Navon-VeneziaS, Schwartz D, Carmeli Y. High levels of antimicrobial co-resistance among extended spectrum beta lactamase producing Enterobacteriaceae. Antimicrob Agents and Chemother 2005; 5: 2137-9.
29.Morosini M, Castillo MG, Coque TM et al. Antimicrobial co-resistance in Extended spectrum Beta Lactamase producing Enterobacteriaceae and in vitro activity of Tigecycline. Antimicrob Agents and Chemother 2006; 8: 2695-9.
30.Grover SS, Sharma M, Chattopadhya D, Kapoor H, Pasha ST, Singh G. Phenotypic and genotypic detection of ESBL mediated cephalosporin resistance in Klebsiella pneumoniae: emergence of high resistance against cefepime, the fourth generation cephalosporin. J Infect Dis 2006; 53(4): 279-88.
31.Mathai D, Rhomberg PR, Biedenbach DJ, Jones RN, India Antimicrobial Resistance Study Group. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against recent clinical isolates from India: a survey of ten medical center laboratories. Diagn Microbiol Infect Dis 2002; 44(4): 367-77.
32.Mohanty S, Singhal R, Sood S, Dhawan B, Das BK, Kapil A. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria. Indian J Med Res 2005; 122(5): 425-42.
Article citation:-
Modi Syamal & Chachan Smriti. Phenotypic characterization and detection of extended spectrum β-lactamase production in urinary isolates from UTI patients at a medical centre in Patna, India. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 June; 31(31): 1184-1191.
Copyright © 2013 Modi Syamal & Chachan Smriti. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.